DK1601355T3 - Diagnostisk metode til forudsigelse af nyretransplantationsafstödning - Google Patents
Diagnostisk metode til forudsigelse af nyretransplantationsafstödningInfo
- Publication number
- DK1601355T3 DK1601355T3 DK04716242T DK04716242T DK1601355T3 DK 1601355 T3 DK1601355 T3 DK 1601355T3 DK 04716242 T DK04716242 T DK 04716242T DK 04716242 T DK04716242 T DK 04716242T DK 1601355 T3 DK1601355 T3 DK 1601355T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnostic method
- transplant rejection
- renal transplant
- predicting renal
- predicting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000058A ITFI20030058A1 (it) | 2003-03-06 | 2003-03-06 | Formulazioni farmaceutiche contenenti tiazolidinedioni |
PCT/EP2004/002069 WO2004078175A2 (en) | 2003-03-06 | 2004-03-02 | Pharmaceutical preparations containing thiazolidinediones for the treatment or prevention of ip-10 mediated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1601355T3 true DK1601355T3 (da) | 2007-12-17 |
Family
ID=32948189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04716242T DK1601355T3 (da) | 2003-03-06 | 2004-03-02 | Diagnostisk metode til forudsigelse af nyretransplantationsafstödning |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060287372A1 (pt) |
EP (2) | EP1601355B1 (pt) |
JP (1) | JP2006519799A (pt) |
AT (1) | ATE368859T1 (pt) |
AU (1) | AU2004216823B2 (pt) |
CA (1) | CA2518199A1 (pt) |
CY (1) | CY1108098T1 (pt) |
DE (1) | DE602004007895T2 (pt) |
DK (1) | DK1601355T3 (pt) |
ES (1) | ES2290678T3 (pt) |
IT (1) | ITFI20030058A1 (pt) |
PL (1) | PL1601355T3 (pt) |
PT (1) | PT1601355E (pt) |
WO (1) | WO2004078175A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
ITFI20040243A1 (it) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | Metodo diagnostico per la previsione di rigetto di organo trapiantato |
GB0504206D0 (en) * | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
JP5149271B2 (ja) | 2006-03-16 | 2013-02-20 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体 |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CN101848893B (zh) | 2007-09-14 | 2012-06-06 | 奥梅-杨森制药有限公司 | 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮 |
EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
MX2010005110A (es) | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
US8691849B2 (en) | 2008-09-02 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
CN102186477B (zh) | 2008-10-16 | 2013-07-17 | 奥梅-杨森制药有限公司 | 作为代谢型谷氨酸受体调节剂的吲哚和苯并吗啉衍生物 |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MY153912A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
BRPI1012870B8 (pt) | 2009-05-12 | 2021-05-25 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostericos positivos de receptores de mglur2 e composição farmacêutica |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
SI3431106T1 (sl) | 2014-01-21 | 2021-03-31 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne alosterične modulatorje metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
US20190350907A1 (en) * | 2017-01-16 | 2019-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE210663T1 (de) * | 1994-06-20 | 2001-12-15 | Takeda Chemical Industries Ltd | Kondensierte imidazolderivate, ihre herstellung und verwendung |
CZ388598A3 (cs) * | 1996-05-31 | 1999-07-14 | Sankyo Company, Limited | Léčivo proti autoimunní nemoci |
GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6369098B1 (en) * | 1999-10-05 | 2002-04-09 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
US20040224306A1 (en) * | 1999-11-30 | 2004-11-11 | Frederich-Wilhelm Kuhne | Evaluating and predicting clinical outcomes by gene expression analysis |
WO2001062238A2 (en) * | 2000-02-24 | 2001-08-30 | San Diego State University | Ppar gamma agonists for the treatment of liver inflammatory disorders |
US20020019344A1 (en) * | 2000-02-26 | 2002-02-14 | Pershadsingh Harrihar A. | Methods of preventing allograft rejection |
US20020018776A1 (en) * | 2000-04-14 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CXCR3 function |
FR2823225B1 (fr) * | 2001-04-04 | 2004-09-17 | Pierre Desreumaux | Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant |
US7244555B2 (en) * | 2002-05-14 | 2007-07-17 | Renovak Inc | Systems and methods for identifying organ transplant risk |
-
2003
- 2003-03-06 IT IT000058A patent/ITFI20030058A1/it unknown
-
2004
- 2004-03-02 PT PT04716242T patent/PT1601355E/pt unknown
- 2004-03-02 CA CA002518199A patent/CA2518199A1/en not_active Abandoned
- 2004-03-02 DK DK04716242T patent/DK1601355T3/da active
- 2004-03-02 US US10/548,514 patent/US20060287372A1/en not_active Abandoned
- 2004-03-02 AU AU2004216823A patent/AU2004216823B2/en not_active Ceased
- 2004-03-02 JP JP2006504502A patent/JP2006519799A/ja active Pending
- 2004-03-02 ES ES04716242T patent/ES2290678T3/es not_active Expired - Lifetime
- 2004-03-02 AT AT04716242T patent/ATE368859T1/de not_active IP Right Cessation
- 2004-03-02 EP EP04716242A patent/EP1601355B1/en not_active Expired - Lifetime
- 2004-03-02 PL PL04716242T patent/PL1601355T3/pl unknown
- 2004-03-02 EP EP07109545A patent/EP1830191A3/en not_active Withdrawn
- 2004-03-02 WO PCT/EP2004/002069 patent/WO2004078175A2/en active IP Right Grant
- 2004-03-02 DE DE602004007895T patent/DE602004007895T2/de not_active Expired - Lifetime
-
2007
- 2007-10-15 CY CY20071101331T patent/CY1108098T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1108098T1 (el) | 2014-02-12 |
EP1830191A2 (en) | 2007-09-05 |
AU2004216823B2 (en) | 2009-07-16 |
AU2004216823A1 (en) | 2004-09-16 |
US20060287372A1 (en) | 2006-12-21 |
ES2290678T3 (es) | 2008-02-16 |
EP1601355B1 (en) | 2007-08-01 |
JP2006519799A (ja) | 2006-08-31 |
DE602004007895D1 (de) | 2007-09-13 |
EP1830191A3 (en) | 2007-10-03 |
WO2004078175A2 (en) | 2004-09-16 |
ATE368859T1 (de) | 2007-08-15 |
CA2518199A1 (en) | 2004-09-16 |
PL1601355T3 (pl) | 2007-12-31 |
WO2004078175A3 (en) | 2004-12-09 |
DE602004007895T2 (de) | 2008-04-17 |
EP1601355A2 (en) | 2005-12-07 |
PT1601355E (pt) | 2007-11-15 |
ITFI20030058A1 (it) | 2004-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108098T1 (el) | Διαγνωστικη μεθοδος για την προβλεψη της απορριψης μεταμοσχευσεων νεφρου | |
CY1116107T1 (el) | Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων | |
DE602004020332D1 (de) | Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
DK1656372T3 (da) | 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme | |
FR2850009B1 (fr) | Ensemble de traitement de la degenerescence d'un disque intervertebral | |
DK1131096T3 (da) | Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
ATE457989T1 (de) | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit | |
ATE417037T1 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
ATE537826T1 (de) | Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung | |
ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
DK1594833T3 (da) | 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme | |
EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
DE60225561D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung | |
EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
DK1592384T3 (da) | Cop 1 til behandling af inflammatoriske tarmsygdomme | |
FR2852229B1 (fr) | Prothese totale d'epaule. | |
EA200501690A1 (ru) | Композиция, включающая ингибитор pde4 и ингибитор pde5 | |
ATE313540T1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
NO20041059L (no) | Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens | |
DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
DE60218375D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen | |
FR2860154B1 (fr) | Composition pour le traitement de la mauvaise haleine | |
DE60309719D1 (de) | N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis |